Agreements

Date: 2017-08-29

Type of information: Licensing agreement

Compound: DS-5010

Company: Boston Pharmaceuticals (USA - MA) Daiichi Sankyo (Japan)

Therapeutic area: Cancer - Oncology

Type agreement: licensing

Action mechanism: RET inhibitor/kinase inhibitor. DS-5010 is a highly selective and potent RET (ret proto-oncogene) kinase inhibitor in late preclinical development. RET rearrangements and activating mutations are associated with several types of cancer, including non-small cell lung cancer, colorectal cancer and thyroid cancer.

Disease:

Details: • On August 28, 2017, Daiichi Sankyo and Boston Pharmaceuticals announced they have entered into a worldwide licensing agreement for Daiichi Sankyo’s novel RET inhibitor, DS-5010. Under the terms of the agreement, Daiichi Sankyo grants Boston Pharmaceuticals worldwide rights for the research, development, manufacturing and commercialization of DS-5010. Daiichi Sankyo will collaborate with Boston Pharmaceuticals to complete preclinical studies to support an Investigational New Drug Application to regulatory authorities and initiation of the clinical program, after which Boston Pharmaceuticals will be responsible for all activities related to DS-5010. DS-5010 is now the fifth candidate in Boston Pharmaceuticals pipeline.

Financial terms:

• Daiichi Sankyo will receive an upfront payment and is eligible for clinical, regulatory and sales milestone payments, as well as royalties on net sales worldwide. Financial terms of the agreement were not disclosed.

Latest news:

Is general: Yes